Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Temsirolimus dosing regimens in relapsed/refractory mantle cell lymphoma
NCT01180049Phase 4Completed
- Sponsor
- Pfizer
- Start
- Mar 2011
- Primary completion
- Nov 2015
- Modality
- Small Molecules
- Countries
- 11
01
Overview
Phase 4, randomised, open-label trial of temsirolimus in mantle cell lymphoma (MCL) (2 arms), sponsored by Pfizer. Primary endpoint: Independently Assessed Progression-free Survival at 15 months. Started Mar 2011; status: completed.
02
Drugs
temsirolimus
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT01180049.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01180049.